MX2011013507A - Nuevos agonistas del gpr 119. - Google Patents

Nuevos agonistas del gpr 119.

Info

Publication number
MX2011013507A
MX2011013507A MX2011013507A MX2011013507A MX2011013507A MX 2011013507 A MX2011013507 A MX 2011013507A MX 2011013507 A MX2011013507 A MX 2011013507A MX 2011013507 A MX2011013507 A MX 2011013507A MX 2011013507 A MX2011013507 A MX 2011013507A
Authority
MX
Mexico
Prior art keywords
agonists
compounds
obesity
diabetes
pharmaceutically acceptable
Prior art date
Application number
MX2011013507A
Other languages
English (en)
Inventor
Harikishore Pingali
Pandurang Zaware
Mukul Jain
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2011013507A publication Critical patent/MX2011013507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente invención se relaciona con nuevos agonistas del GPR 119 que tienen la fórmula general (I), con sus sales farmacéuticamente aceptables, solvatos farmacéuticamente aceptables, enantiómeros, estereoisómeros y polimorfos. La invención también se relaciona con procesos para la preparación de los compuestos de la invención, preparaciones farmacéuticas que contienen los compuestos y con métodos para tratar la diabetes y la obesidad utilizando los compuestos de la invención. La presente invención está enfocada a los agonistas del receptor acoplado a la proteína G (GPCR - G-protein coupled receptor) que son útiles para el tratamiento de obesidad, diabetes y trastornos metabólicos relacionados.
MX2011013507A 2009-06-18 2010-06-17 Nuevos agonistas del gpr 119. MX2011013507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1458MU2009 2009-06-18
PCT/IN2010/000418 WO2010146605A1 (en) 2009-06-18 2010-06-17 Novel gpr 119 agonists

Publications (1)

Publication Number Publication Date
MX2011013507A true MX2011013507A (es) 2012-03-29

Family

ID=42828999

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013507A MX2011013507A (es) 2009-06-18 2010-06-17 Nuevos agonistas del gpr 119.

Country Status (15)

Country Link
US (1) US8772302B2 (es)
EP (1) EP2445904B1 (es)
JP (1) JP5538528B2 (es)
KR (1) KR101432396B1 (es)
CN (1) CN102803255A (es)
AU (1) AU2010261341B2 (es)
CA (1) CA2765822A1 (es)
EA (1) EA201270039A1 (es)
IL (1) IL217064A0 (es)
MX (1) MX2011013507A (es)
NZ (1) NZ597668A (es)
SG (1) SG176865A1 (es)
UA (1) UA104188C2 (es)
WO (1) WO2010146605A1 (es)
ZA (1) ZA201200063B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102731492B (zh) * 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
CA2836487A1 (en) * 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
AU2012271009A1 (en) 2011-06-16 2013-11-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
US9422266B2 (en) 2011-09-30 2016-08-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
AU2012339870B2 (en) 2011-11-15 2017-06-29 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
WO2013154163A1 (ja) * 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
KR101705390B1 (ko) 2012-06-25 2017-02-09 강원대학교산학협력단 이중환 구조를 갖는 신규한 ｇｐｃｒ 효능제
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP2006516572A (ja) 2003-01-14 2006-07-06 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての１，２，３−トリ置換アリール誘導体および１，２，３−トリ置換ヘテロアリール誘導体ならびにこれらの誘導体に関連する糖尿病および高血糖のような障害の予防および処置
UA92450C2 (ru) * 2003-01-14 2010-11-10 Арена Фармасьютикалз, Инк. 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
UA86943C2 (ru) * 2003-07-11 2009-06-10 Арена Фармасьютикалз, Инк. Тризамещенные производные арилов и гетероарилов как модуляторы метаболизма и профилактика и лечение связанных с ними нарушений
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP5465177B2 (ja) * 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
US20110263557A1 (en) * 2008-04-07 2011-10-27 Irm Llc Compounds and compositions as modulators of gpr119 activity

Also Published As

Publication number Publication date
EP2445904B1 (en) 2013-09-11
JP5538528B2 (ja) 2014-07-02
CN102803255A (zh) 2012-11-28
WO2010146605A1 (en) 2010-12-23
US8772302B2 (en) 2014-07-08
UA104188C2 (en) 2014-01-10
US20120122905A1 (en) 2012-05-17
AU2010261341A1 (en) 2012-02-02
CA2765822A1 (en) 2010-12-23
EA201270039A1 (ru) 2012-07-30
NZ597668A (en) 2014-01-31
EP2445904A1 (en) 2012-05-02
IL217064A0 (en) 2012-02-29
SG176865A1 (en) 2012-01-30
JP2012530693A (ja) 2012-12-06
KR20120034732A (ko) 2012-04-12
ZA201200063B (en) 2012-09-26
AU2010261341B2 (en) 2014-02-06
KR101432396B1 (ko) 2014-08-20

Similar Documents

Publication Publication Date Title
UA104188C2 (en) Gpr 119 agonists
EA015805B9 (ru) Пиперидиновые агонисты gpcr
NO20083500L (no) 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
MY146924A (en) Substituted imidazoheterocycles
HK1158192A1 (en) Piperidine gpcr agonists
EA023861B3 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
HK1157329A1 (en) Piperidinyl gpcr agonists
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
NO20092103L (no) Tetrahydrocyklopenta[B]indolforbindelser som androgenreseptormodulatorer
EA201070864A1 (ru) Новые гетероциклические соединения
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MX353625B (es) Combinaciones de agonistas del receptor de serotonina para el tratamiento de trastornos de movimiento.
IN2012DN03042A (es)
WO2009118765A8 (en) Novel monoamine re-uptake inhibitor
ZA200810031B (en) 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments
EA201270421A1 (ru) 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
MX2012003394A (es) Analogos de la nicotinamida de o-bencilo como moduladores alostéricos positivos del mglur5.

Legal Events

Date Code Title Description
FG Grant or registration